CD8A and metabolic disease: The activation of MTOR regulates various effector functions of CD4+ and CD8+ T cells, and MTOR inhibitors (i.e., rapamycin) are used as potential immunosuppressive therapeutics for organ transplants, metabolic diseases, and various autoimmune disorders [25].